Clinical Trials
710 trialsiROC
University College, London
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
P3BC
Icahn School of Medicine at Mount Sinai
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
AstraZeneca
Holmium Laser En-Bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle- Invasive Bladder Cancer
Beni-Suef University
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study
University of Kansas Medical Center
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
TraveraRTGx
Travera Inc
VICKI
Institut Mutualiste Montsouris
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
IRIS
University of Pisa
AVENANCE
Pfizer
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
UNC Lineberger Comprehensive Cancer Center
Recovery Support for Bladder Cancer Patients and Caregivers
Northwell Health
VISIOCYT2
Institut Paoli-Calmettes
COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT
University of Gaziantep
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
Memorial Sloan Kettering Cancer Center
NICSA
Aarhus University Hospital
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
Aarhus University Hospital
TURBT
Dr. Lutfi Kirdar Kartal Training and Research Hospital
MAINTAIN
Aarhus University Hospital
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
H. Lee Moffitt Cancer Center and Research Institute
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Memorial Sloan Kettering Cancer Center
KEYNOTE-B15
Merck Sharp & Dohme LLC
PREPARE
Institut Bergonié
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor
Lahore General Hospital
HYBRID
Institute of Cancer Research, United Kingdom
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
PERTINENCE
Institut Cancerologie de l'Ouest
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
Henan Cancer Hospital
QSCO
University Hospital, Toulouse
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Histopathological Findings in En-Bloc vs Conventional Transurethral Resection of Bladder Tumors.
Ain Shams University
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
UNC Lineberger Comprehensive Cancer Center
Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Merck Sharp & Dohme LLC
SBCT
University of Zurich
WATCH
University of Pittsburgh
AYAConnect
UNC Lineberger Comprehensive Cancer Center
VESPER
University Hospital, Rouen
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Impact of Intelligent Nursing Based on Health Cloud Platform on Active Health Management of Urostomy Patients
Sir Run Run Shaw Hospital
MORE
Icahn School of Medicine at Mount Sinai